hotspot -WSS

hotspot

author：fashion 2025-09-30 17:46:25 - browse：8448

An effective treatment for Alzheimer’s disease has long been a holy grail in the pharmaceutical industry. In early June, some hope appeared when the FDA agreed that the anti-amyloid antibody lecanemab (to be sold by Eisai as Leqembi) outperformed placebo in trials. It is expected to receive full approval by July 6.

But this may not necessarily be purely good news.

On the latest episode of the “First Opinion Podcast,” physician and professor Jason Karlawish argues that lecanemab and other promising new drugs, such as donanemab, will introduce complicated issues into the field of Alzheimer’s care. These medications require a great deal of testing and patient monitoring, trained physicians, and other resources in a system that is already stretched thin.

“Dr. Karlawish’s dream of reason would be … a training module for physicians to learn the key things they need to learn and then self-assess their comfort with the drug,” Karlawish said. “But that’s Karlawish’s dream of reason in a world that seems increasingly less reasonable sometimes.”

Karlawish is a professor of medicine, medical ethics and health policy, and neurology at the University of Pennsylvania’s Perelman School of Medicine. The conversation is based off his recent First Opinion, “The FDA needs a risk evaluation and mitigation strategy for Alzheimer’s drug lecanemab.“

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Stitcher, Google Play, or wherever you get your podcasts.

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Snackable artificial intelligence, expert AI, and the pharma industry

explore

leisure time

WSS

CDC panel: People 65 and older should get a Covid spring booster shot

Virtual repurposing can help discover new uses for existing drugs

The 10 drugs up first for Medicare price negotiation

Change Healthcare cyberattack shows risk of industry consolidation

Ethical issues complicate the benefits of medical crowdfunding

ALS advocates say criticism of new drugs misses bigger picture

explore

hotspot

Wikipedia

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Amazon on where the company's health care bets are headed next

Sports medicine is finally prioritizing gender equality

Snackable artificial intelligence, expert AI, and the pharma industry

Drug repurposing or repositioning? The language matters

Humana sues Biden admin over Medicare Advantage audit rule

As demand for Covid shots wanes, Moderna seeks its next success

ALS advocates say criticism of new drugs misses bigger picture

Apple is now the first public company to be valued at $3 trillion

NEJM study measures Covid brain fog, impact on IQ

explore

Medicaid rebukes states for mistakenly disenrolling children

Why Novartis is changing the name of its research labs

CDC advisory group OKs chikungunya vaccine

Stem cell treatment guidelines are released by FDA

Medicare Advantage isn’t working — for anyone

A rare thyroid diagnosis led to unexpected, all

explore

entertainment

leisure time

knowledge